FOLD vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FOLD exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While the company maintains impressive gross margins (88.5%) and revenue growth (23.7%), these are offset by a catastrophic collapse in earnings growth (-95.5% YoY) and negative ROE. The stock is currently trading at a 52-week high despite a bearish technical trend score (10/100) and aggressive insider selling by the CEO and other officers. The disconnect between the current price and the underlying deterministic health metrics suggests a high risk of a price correction.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
FOLD vs LLY: Head-to-Head Comparison
This page compares Amicus Therapeutics, Inc. (FOLD) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.